Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients

NCT04176328 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.

Sponsor

Neupharma Srl

Collaborators

[object Object]
[object Object]
[object Object]